Document is current
Any future updates will be listed below
-
Authors
Gu, Xinchun https://orcid.org/0000-0002-2202-6792
Agrawal, Utkarsh
Midgley, William
Bedston, Stuart https://orcid.org/0000-0002-5635-5957
Anand, Sneha N.
Goudie, Rosalind
Byford, Rachel
Joy, Mark
Jamie, Gavin https://orcid.org/0000-0001-9147-7784
Hoang, Uy
Ordóñez-Mena, Jose M.
Robertson, Chris https://orcid.org/0000-0001-6848-5241
Hobbs, F. D. Richard
Akbari, Ashley https://orcid.org/0000-0003-0814-0801
Sheikh, Aziz https://orcid.org/0000-0001-7022-3056
de Lusignan, Simon https://orcid.org/0000-0002-8553-2641
-
Funding
Funding for this research was provided by:
UK Research and Innovation (grant ref MC_PC_20058) Health Data Research UK
- License Information
-
More Information
Article History
Received: 12 February 2024
Accepted: 25 July 2024
First Online: 14 August 2024
Competing interests
: A.S. and C.R. are members of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group. A.S. is a member of the NERVTAG Risk Stratification Subgroup and an unfunded member of AstraZeneca’s COVID-19 strategic consultancy group, the Thrombocytopenia Taskforce. C.R. is a member of the Scientific Pandemic Influenza Group on Modelling and the Medicines and Healthcare Products Regulatory Agency COVID-19 Vaccine Benefit and Risk Working Group. S.deL has received funding through his University from Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Sanofi, Seqirus, and Takeda, and has been a member of advisory boards for Astra- Zeneca, Sanofi, and Seqirus. S.deL. is the Director of the Oxford-RCGP RSC. All other authors report no competing interests.
